Published in Genome Res on May 29, 2015
Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nat Methods (2015) 1.27
Editing the epigenome: technologies for programmable transcription and epigenetic modulation. Nat Methods (2016) 1.24
Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation. Nat Rev Mol Cell Biol (2015) 1.20
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes. Cell (2016) 1.08
Making sense of GWAS: using epigenomics and genome engineering to understand the functional relevance of SNPs in non-coding regions of the human genome. Epigenetics Chromatin (2015) 0.99
Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity. Mol Cell (2016) 0.91
Enabling functional genomics with genome engineering. Genome Res (2015) 0.90
CRISPR-mediated Activation of Latent HIV-1 Expression. Mol Ther (2015) 0.88
The New State of the Art: Cas9 for Gene Activation and Repression. Mol Cell Biol (2015) 0.87
Targeted Epigenetic Remodeling of Endogenous Loci by CRISPR/Cas9-Based Transcriptional Activators Directly Converts Fibroblasts to Neuronal Cells. Cell Stem Cell (2016) 0.85
Probing the impact of chromatin conformation on genome editing tools. Nucleic Acids Res (2016) 0.84
Real-time observation of DNA recognition and rejection by the RNA-guided endonuclease Cas9. Nat Commun (2016) 0.81
Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies? Mol Oncol (2016) 0.81
Genome editing: the road of CRISPR/Cas9 from bench to clinic. Exp Mol Med (2016) 0.77
Reactivation of Latent HIV-1 Expression by Engineered TALE Transcription Factors. PLoS One (2016) 0.77
Genome Engineering with TALE and CRISPR Systems in Neuroscience. Front Genet (2016) 0.75
Development of an AAV9 coding for a 3XFLAG-TALEfrat#8-VP64 able to increase in vivo the human frataxin in YG8R mice. Gene Ther (2016) 0.75
Genetic and epigenetic control of gene expression by CRISPR-Cas systems. F1000Res (2017) 0.75
Identifying ultrasensitive HGF dose-response functions in a 3D mammalian system for synthetic morphogenesis. Sci Rep (2016) 0.75
Editing the Neuronal Genome: a CRISPR View of Chromatin Regulation in Neuronal Development, Function, and Plasticity. Yale J Biol Med (2016) 0.75
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol (2009) 235.12
Genome-wide mapping of in vivo protein-DNA interactions. Science (2007) 64.92
Differential expression analysis for sequence count data. Genome Biol (2010) 64.56
Multiplex genome engineering using CRISPR/Cas systems. Science (2013) 55.53
Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics (2010) 52.01
Model-based analysis of ChIP-Seq (MACS). Genome Biol (2008) 51.63
RNA-guided human genome engineering via Cas9. Science (2013) 48.29
A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science (2012) 48.17
Fitting a mixture model by expectation maximization to discover motifs in biopolymers. Proc Int Conf Intell Syst Mol Biol (1994) 37.96
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol (2014) 27.48
A TALE nuclease architecture for efficient genome editing. Nat Biotechnol (2010) 26.47
Breaking the code of DNA binding specificity of TAL-type III effectors. Science (2009) 22.33
Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol (2013) 21.32
A simple cipher governs DNA recognition by TAL effectors. Science (2009) 19.99
DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol (2013) 19.99
High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol (2013) 18.01
RNA-guided genetic silencing systems in bacteria and archaea. Nature (2012) 17.12
Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res (2011) 16.53
RNA-programmed genome editing in human cells. Elife (2013) 14.82
Targeting DNA double-strand breaks with TAL effector nucleases. Genetics (2010) 14.49
Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol (2013) 14.28
Development and applications of CRISPR-Cas9 for genome engineering. Cell (2014) 13.50
Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell (2013) 13.43
Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat Biotechnol (2011) 12.86
Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol (2011) 11.76
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol (2013) 11.58
CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol (2013) 11.35
CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell (2013) 9.55
TAL effectors: customizable proteins for DNA targeting. Science (2011) 9.47
CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol (2014) 9.18
ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia. Genome Res (2012) 9.13
High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol (2013) 8.40
Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol (2014) 6.85
Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res (2013) 6.19
Optical control of mammalian endogenous transcription and epigenetic states. Nature (2013) 6.09
DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature (2014) 5.70
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol (2014) 5.69
Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell (2014) 5.43
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature (2014) 5.19
Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nat Biotechnol (2014) 5.07
RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods (2013) 4.85
CRISPR RNA-guided activation of endogenous human genes. Nat Methods (2013) 4.69
Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nat Methods (2013) 4.61
TAL Effector-Nucleotide Targeter (TALE-NT) 2.0: tools for TAL effector design and target prediction. Nucleic Acids Res (2012) 4.45
Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat Biotechnol (2014) 4.16
CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res (2013) 4.11
Locus-specific editing of histone modifications at endogenous enhancers. Nat Biotechnol (2013) 3.82
Comprehensive interrogation of natural TALE DNA-binding modules and transcriptional repressor domains. Nat Commun (2012) 3.60
Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat Biotechnol (2015) 3.56
DNase-seq: a high-resolution technique for mapping active gene regulatory elements across the genome from mammalian cells. Cold Spring Harb Protoc (2010) 3.54
Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res (2013) 3.50
Regulation of an endogenous locus using a panel of designed zinc finger proteins targeted to accessible chromatin regions. Activation of vascular endothelial growth factor A. J Biol Chem (2001) 3.38
Synergistic and tunable human gene activation by combinations of synthetic transcription factors. Nat Methods (2013) 3.26
Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat Biotechnol (2014) 2.99
Robust, synergistic regulation of human gene expression using TALE activators. Nat Methods (2013) 2.89
Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. Nat Biotechnol (2013) 2.89
Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic modifiers. Nucleic Acids Res (2012) 2.83
Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nat Methods (2015) 2.29
A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell (2014) 2.27
Functional annotation of native enhancers with a Cas9-histone demethylase fusion. Nat Methods (2015) 2.22
Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat Biotechnol (2015) 2.03
Effects of sequence variation on differential allelic transcription factor occupancy and gene expression. Genome Res (2012) 1.99
Quantitative analysis of TALE-DNA interactions suggests polarity effects. Nucleic Acids Res (2013) 1.88
TALEN-based gene correction for epidermolysis bullosa. Mol Ther (2013) 1.84
A split-Cas9 architecture for inducible genome editing and transcription modulation. Nat Biotechnol (2015) 1.83
Highly efficient Cas9-mediated transcriptional programming. Nat Methods (2015) 1.81
Transposase mediated construction of RNA-seq libraries. Genome Res (2011) 1.66
Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity. Nat Methods (2014) 1.66
Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. Mol Ther (2013) 1.63
Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector. Nucleic Acids Res (2014) 1.59
Tunable and multifunctional eukaryotic transcription factors based on CRISPR/Cas. ACS Synth Biol (2013) 1.58
A light-inducible CRISPR-Cas9 system for control of endogenous gene activation. Nat Chem Biol (2015) 1.48
An online bioinformatics tool predicts zinc finger and TALE nuclease off-target cleavage. Nucleic Acids Res (2013) 1.45
Genome-wide identification of CRISPR/Cas9 off-targets in human genome. Cell Res (2014) 1.32
Comparison of TALE designer transcription factors and the CRISPR/dCas9 in regulation of gene expression by targeting enhancers. Nucleic Acids Res (2014) 1.25
Reprogramming to pluripotency using designer TALE transcription factors targeting enhancers. Stem Cell Reports (2013) 1.22
A genome-wide analysis of Cas9 binding specificity using ChIP-seq and targeted sequence capture. Nucleic Acids Res (2015) 1.20
A CRISPR/Cas9-based system for reprogramming cell lineage specification. Stem Cell Reports (2014) 1.09
Regulation of endogenous human gene expression by ligand-inducible TALE transcription factors. ACS Synth Biol (2013) 0.94
Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression. Methods (2014) 0.93
Activating human genes with zinc finger proteins, transcription activator-like effectors and CRISPR/Cas9 for gene therapy and regenerative medicine. Expert Opin Ther Targets (2014) 0.90
Enabling functional genomics with genome engineering. Genome Res (2015) 0.90